Riverain Technologies

The software is the product. ClearRead applies deep learning vessel suppression to make nodules visible that vessels would otherwise obscure, paired with detection, and the company sells no scanner or services layer. The vessel suppression approach is itself the technical thesis: rather than only classifying findings, the model alters the image so both the algorithm and the human read better, which is a distinct mechanism from pure detection overlays.

Notable for the concurrent read model specifically. Most computer aided detection is cleared as a second read, running after the radiologist's initial interpretation to avoid biasing it; ClearRead was cleared to support concurrent reading, meaning output is available alongside the initial read. That is a deliberate design tradeoff, faster workflow against greater exposure to automation bias, and it sits at the opposite end from Ibex, whose second read sequencing structurally eliminates that bias. The radiologist retains the diagnosis in both cases, but buyers should understand the difference, because concurrent presentation changes how much the tool can influence the human.

The clearance documentation is inspectable and reasonably detailed, including performance estimates broken out by nodule type, residual analysis showing little performance impact across slice thickness values, and disclosure of the micro nodule filtering option with its site configurable threshold capped at 5mm to keep behavior within labeled performance. Acquisition normalization is described as handling scans across manufacturers and protocols without per device tuning. Training data scale and composition are not published, and there is no third party head to head benchmarking, so transparency is strong in the regulatory record and lighter in marketing materials.

The core evidence is a multi reader multi case clinical trial supporting the original clearance, reporting a 29 percent reduction in missed actionable nodules, which measures the right thing for a detection aid: change in reader performance, not standalone algorithm accuracy. An independent study led by University of Washington School of Medicine radiology researchers examined the vessel suppression product, and the company reports commercial traction including expansion across eight countries and roughly 50 new customers in 2024. The evidence base is real but thinner and older than newer entrants with dozens of publications, and outcome level data is absent.

No specific PHI handling or data governance framework was located in the materials reviewed.

No HIPAA or BAA commitment was located in public materials, despite the vendor being US headquartered and selling into US radiology, so terms would need to be established directly.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located. The FDA submission references ISO 13485:2016 with MDSAP, which covers device quality management rather than information security.

Genuinely cleared and maintained over time, though this is an older generation of authorization than most vendors indexed here. ClearRead CT was cleared in 2016 as the first device supporting concurrent reading with detection across solid, subsolid, and ground glass nodules, with subsequent clearances including ClearRead CT Compare, K221612, and a 2025 clearance extending to coronary artery calcium scoring on ungated non contrast scans. Available for sale in the United States, Canada, and Europe. Solid multi clearance record; graded B rather than A because the portfolio is narrow and the foundational clearance predates the current generation of imaging AI standards such as Predetermined Change Control Plans.

The clearance record includes performance analysis across slice thickness and across scans from multiple manufacturers and acquisition protocols, which addresses technical generalization. What is absent is any governance framework, post market monitoring commitment, or demographic subgroup analysis. Technical robustness tested, population level performance unexamined publicly.

Deployment friction is low by design. The software is described as installing into the clinical environment without new hardware and without customized tuning to specific devices or protocols, processing CT scans across a wide range of manufacturers and acquisition protocols, and the company markets it as an enterprise ready solution across a healthcare network. This is PACS and imaging workflow integration; no EHR integration is claimed or applicable.

Described as installing into the existing clinical environment without new hardware, which implies on premise or near premise deployment and therefore likely keeps imaging data inside the institution, an advantage over cloud only competitors for residency sensitive buyers. Specific tenancy, hosting, and residency terms are not published, so this is inferred from deployment description rather than stated.

No pricing is published. The company discloses growth figures including 147 percent growth in 2024, expansion across eight countries, and nearly 50 new customers added, which speaks to trajectory but not cost. Nothing on per study, per site, or licensing structure.

Deliberately narrow: cardiothoracic imaging, centered on lung nodule detection in chest CT and radiography, with a recent extension into coronary artery calcium scoring that enables opportunistic cardiac screening from scans acquired for other reasons. That opportunistic screening angle is a genuine workflow advantage, but coverage does not extend beyond the chest, and the vendor does not compete on breadth with multi finding platforms covering neuro, musculoskeletal, and emergency triage.